For the Inventor, By the Inventor

Enter assignee name

Hong Kong, China

Ascentage Pharma Group Corp Limited

USPTO Granted Patents = 20

CIPO Patents = 1

EPO Patents = 8

Trademarks = 13

Forward Citations = 7

Loading Chart...

Loading Chart...

60 inventors (with patents filed for the assignee):

Dajun Yang (8 out of 17 patents)

Yifan Zhai (8 out of 17 patents)

Douglas Dong Fang (6 out of 12 patents)

4. Jianfeng Wen (5 out of 6 patents)

5. Ming Guo (4 out of 6 patents)

6. Qiuqiong Tang (4 out of 7 patents)

7. Tianzhu Wu (3 out of 4 patents)

8. Huirong Lu (3 out of 3 patents)

9. Jianpeng Feng (3 out of 4 patents)

10. Chao-Yie Yang (3 out of 15 patents)

11. Yunlong Zhou (3 out of 7 patents)

12. Yu Jing (3 out of 7 patents)

13. Shaomeng Wang (3 out of 77 patents)

14. Guozhi Tang (3 out of 4 patents)

15. Chao Li (3 out of 6 patents)

20 patents: Sort by Forward Citations

1. 12370197 - Combination product of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases (2025-07-29),

2. 12358912 - Crystalline forms or amorphous forms of N-(phenyl sulfonyl) benzamide compounds or its salts or solvates (2025-07-15),

3. 12343352 - N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors (2025-07-01),

4. 12319703 - Macrocyclic fused pyrazoles as Mcl-1 inhibitors (2025-06-03),

5. 12287338 - Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway (2025-04-29),

6. 12233047 - Pharmaceutical combination and use thereof (2025-02-25),

7. 12221427 - Preparation method of (5-fluoro-2,3-dihydrobenzofuran-4-yl)methanamine or its salt, and intermediates thereof (2025-02-11),

8. 12194024 - Pharmaceutical composition of MDM2 inhibitor and use thereof for preventing and/or treating disease (2025-01-14),

9. 12097195 - Pharmaceutical composition containing alkynyl compound and preparation method and application thereof (2024-09-24),

10. 11987575 - Tricyclic compounds as BCR-ABL inhibitors (2024-05-21),

11. 11872237 - Pharmaceutical composition and preparation method thereof (2024-01-16),

12. 11850239 - MDM2 inhibitor and a platinum compound for cancer treatment (2023-12-26),

13. 11787814 - Method for preparing 2-indolinospirone compound and intermediate thereof (2023-10-17),

14. 11691989 - Macrocyclic indoles as Mcl-1 inhibitors (2023-07-04),

15. 11498928 - Macrocyclic spiroethers as Mcl-1 inhibitors (2022-11-15),

Ascentage Pharma is a global, clinical-stage biopharmaceutical company, focusing on developing innovative drugs, including therapeutics for cancers with unmet medical needs. The company has a robust pipeline of small molecule, protein, and cell therapy programs in various stages of preclinical and clinical development.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

20 Patents

#164 in Hong Kong

#1,303 in China

#30,316 in the World

Hong Kong, China

Ascentage Pharma Group Corp Limited

Forward Citations = 7

60 inventors:

Dajun Yang (8 out of 17 patents)

Yifan Zhai (8 out of 17 patents)

Douglas Dong Fang (6 out of 12 patents)

4. Jianfeng Wen (5 out of 6 patents)

5. Ming Guo (4 out of 6 patents)

Please report any incorrect information to support@idiyas.com

Loading…